Recently a new oral drug is approved for treatment of multiple myeloma. It acts as a selective inhibitor of nuclear expo. Which drug is it ?
Correct Answer: SELINEXOR
Description: SELINEXOR : - It is an oral selective inhibitor of nuclear expo (SINE) compound. - It works by binding to Nuclear expo protein (Expoin 1) and inhibiting the transpo of several proteins (involved in cancer cell growth) from nucleus to cytoplasm. This results in accumulation of tumor suppressor proteins in the cell nucleus. This will reinitiate and amplifies tumor suppressor function and leads to selective induction of apoptosis in cancer cells. - Used for multiple myeloma and Diffuse large B cell lymphoma. POLATUZUMAB : - Antibody targeting the CD 79 B component of the B cell receptor. - Used for relapsed or refractory diffuse large B cell lymphoma. ZANUBRUTINIB : - It is a Bruton tyrosine kinase inhibitor like ibrutinib - Used for Mantle cell lymphoma. FEDRATINIB : - It is a oral JAK 2 inhibitor - Used for MYELOFIBROSIS.
Category:
Pharmacology
Get More
Subject Mock Tests
Practice with over 200,000 questions from various medical subjects and improve your knowledge.
Attempt a mock test nowMock Exam
Take an exam with 100 random questions selected from all subjects to test your knowledge.
Coming SoonGet More
Subject Mock Tests
Try practicing mock tests with over 200,000 questions from various medical subjects.
Attempt a mock test now